Clincosm LogoSign in Get a demo

EBVER/TMC: EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

Sponsor
Andreas Arnold (Other)
Overall Status
Completed
CT.gov ID
NCT01942005
Collaborator
(none)
144
Enrollment
1
Location
51.9
Duration (Months)
2.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    144 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection
    Study Start Date :
    Jan 1, 2010
    Actual Primary Completion Date :
    May 1, 2014
    Actual Study Completion Date :
    May 1, 2014

    Outcome Measures

    Primary Outcome Measures

    1. Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [7 years]

    Secondary Outcome Measures

    1. correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [7 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients in an immunosuppressive condition either by immunosuppressants or by HIV infection
    Exclusion Criteria:
    • written informed consent not given

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Basel, Dermatology Basel Basel Stadt Switzerland 4031

    Sponsors and Collaborators

    • Andreas Arnold

    Investigators

    • Principal Investigator: Andreas Arnold, MD, University Hospital Basel, Dermatology, CH-4031 Basel

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Andreas Arnold, Dr. med. Andreas Arnold, senior physician, University Hospital, Basel, Switzerland
    ClinicalTrials.gov Identifier:
    NCT01942005
    Other Study ID Numbers:
    • 11/10
    First Posted:
    Sep 13, 2013
    Last Update Posted:
    Dec 4, 2014
    Last Verified:
    Dec 1, 2014
    Additional relevant MeSH terms:
    Carcinoma

    Study Results

    No Results Posted as of Dec 4, 2014